Total Funding
53
59
Total FundingPost-IPO Equity raised
Growth Score
0 pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
46632
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Berndt Modig: CEOPast Role: Prosensa, Chief Financial Officer- Jochen Knolle: Chief Scientific and Operating OfficerPast Role: Jerini, Chief Scientific Officer and Head of R&D
About the Company
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing with new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated
indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.
The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.
